PMID- 30697883
OWN - NLM
STAT- MEDLINE
DCOM- 20200114
LR  - 20200114
IS  - 1529-8019 (Electronic)
IS  - 1396-0296 (Linking)
VI  - 32
IP  - 3
DP  - 2019 May
TI  - The efficacy of omalizumab in Cutaneous Mastocytosis: A case series.
PG  - e12848
LID - 10.1111/dth.12848 [doi]
AB  - BACKGROUND: Mastocytosis describes a heterogeneous group of disorders arising 
      from a clonal proliferation of mast cells. Given the lack of curative treatments 
      for the cutaneous form, there is a significant need for superior therapies. 
      Omalizumab is a recombinant DNA-derived humanized IgG monoclonal antibody that 
      selectively binds to human immunoglobulin E (IgE). It represents a potential 
      treatment for the management of cutaneous mastocytosis, which currently has no 
      standard treatment. METHODS: Two patients were treated with subcutaneous 
      omalizumab 300 mg every 4 weeks. DISCUSSION: Patient 1 experienced 50% reduction 
      in cutaneous infiltration and moderate improvement in pruritus. Patient 2 
      underwent 90% complete clearance of cutaneous lesions and reported full 
      resolution of pruritus. The median duration of treatment was 24 weeks and time to 
      response was 8 weeks. No significant changes in tryptase levels were observed. 
      Both patients experienced injection site reactions. CONCLUSION: We provide 
      evidence from two cases supporting the efficacy of IgE-mediated therapy in the 
      treatment of cutaneous mastocytosis. Even at a higher-than-standard dose (300 mg 
      vs. 150 mg), the drug was well-tolerated. As we await the results of pivotal 
      clinical trials, omalizumab appears to be a promising treatment option in 
      patients with cutaneous mastocytosis unresponsive to traditional therapies.
CI  - (c) 2019 Wiley Periodicals, Inc.
FAU - Hinojosa, Tiffany
AU  - Hinojosa T
AUID- ORCID: 0000-0001-5809-698X
AD  - Dermatology Department, Center for Clinical Studies, Houston, Texas.
FAU - Lewis, Daniel J
AU  - Lewis DJ
AD  - Department of Internal Medicine, Memorial Sloan Kettering Cancer Center, New 
      York, New York.
AD  - Department of Dermatology, The University of Texas MD Anderson Cancer Center, 
      Houston, Texas.
FAU - Vangipuram, Ramya
AU  - Vangipuram R
AD  - Department of Dermatology, University of Texas Health Science Center at Houston, 
      Houston, Texas.
FAU - Safeer, Laraib
AU  - Safeer L
AD  - School of Medicine, Baylor College of Medicine, Houston, Texas.
FAU - Mui, Uyen Ngoc
AU  - Mui UN
AD  - Dermatology Department, Center for Clinical Studies, Houston, Texas.
FAU - Haley, Christopher
AU  - Haley C
AD  - Dermatology Department, Center for Clinical Studies, Houston, Texas.
FAU - Konoplev, Sergej
AU  - Konoplev S
AD  - Department of Hematopathology, The University of Texas MD Anderson Cancer Center, 
      Houston, Texas.
FAU - Tyring, Stephen K
AU  - Tyring SK
AD  - Dermatology Department, Center for Clinical Studies, Houston, Texas.
AD  - Department of Dermatology, University of Texas Health Science Center at Houston, 
      Houston, Texas.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20190220
PL  - United States
TA  - Dermatol Ther
JT  - Dermatologic therapy
JID - 9700070
RN  - 0 (Anti-Allergic Agents)
RN  - 2P471X1Z11 (Omalizumab)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Adult
MH  - Anti-Allergic Agents/*administration & dosage/adverse effects/pharmacology
MH  - Female
MH  - Humans
MH  - Immunoglobulin E/immunology
MH  - Injections, Subcutaneous
MH  - Mastocytosis, Cutaneous/*drug therapy/immunology
MH  - Middle Aged
MH  - Omalizumab/*administration & dosage/adverse effects/pharmacology
MH  - Pruritus/drug therapy/etiology
MH  - Treatment Outcome
OTO - NOTNLM
OT  - IgE
OT  - maculopapular cutaneous mastocytosis
OT  - mastocytosis
OT  - omalizumab
EDAT- 2019/01/31 06:00
MHDA- 2020/01/15 06:00
CRDT- 2019/01/31 06:00
PHST- 2018/07/24 00:00 [received]
PHST- 2018/10/12 00:00 [revised]
PHST- 2019/01/26 00:00 [accepted]
PHST- 2019/01/31 06:00 [pubmed]
PHST- 2020/01/15 06:00 [medline]
PHST- 2019/01/31 06:00 [entrez]
AID - 10.1111/dth.12848 [doi]
PST - ppublish
SO  - Dermatol Ther. 2019 May;32(3):e12848. doi: 10.1111/dth.12848. Epub 2019 Feb 20.